Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-31RA siRNA
- Development stage
- Preclinical
- Lead developer
- University of Cincinnati
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
IL-31RA siRNA is a small interfering RNA (siRNA) designed to silence the expression of the interleukin-31 receptor alpha (IL-31RA) subunit. Research presented at the ATS 2025 conference indicates that IL-31RA plays a critical, ligand-independent role in regulating airway smooth muscle cell (ASMC) contraction and airway hyperresponsiveness (AHR) in asthma. By knocking down IL-31RA in human ASMCs, researchers observed a significant reduction in calcium elevation and myosin light chain phosphorylation in response to contractile stimuli like carbachol and histamine. This effect is mediated by the downregulation of cell surface expression of the M3 muscarinic receptor (CHRM3) and Histamine H1 Receptor (H1HR). These findings suggest that targeting IL-31RA with siRNA or other inhibitors could provide a novel therapeutic approach for managing AHR in asthmatic patients.
- Other names
- interleukin-31 receptor alpha siRNAinterleukin31 receptor alpha siRNAinterleukin 31 receptor alpha siRNAIL-31 receptor alpha siRNAIL31 receptor alpha siRNAIL 31 receptor alpha siRNA
02
Targets
IL31RA (IL-31 receptor alpha)
Beyond the preview
Go deeper on IL-31RA siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-31RA siRNA.